Navegando por Palavras-chave "Epilepsia."

Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Efeitos neurobiológicos do tratamento com sakuranetina em camundongos.
    (Universidade Federal de São Paulo (UNIFESP), 2019-09-27) Silva, Wilson Vicente Da [UNIFESP]; Ribeiro, Alessandra Mussi [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    It is recognized that extracts and substances obtained from natural products, such as plants and animal venom, can contribute to the development of model drugs. The use of medicinal plants for the treatment of various is the oldest and most traditional form of therapeutic model in different civilizations. Brazil has a vast plant biodiversity, resulting in a wide heterogeneity of bioactive chemicals that can be isolated and used for medicinal purposes. Many molecules isolated from plant extracts can have pharmacological effects on different biological tissues, such as antioxidant and neuroprotective action on nervous tissue. In this context, sakuranetin (SAK) is a plant-isolated flavonoid, and previous studies have shown that this compound has antiparasitic, anti-inflammatory and antioxidant activity. Thus, the aim of the present study was to investigate the potential anxiolytic and anticonvulsant effects of acute administration of SAK in mice. For this study male Swiss mice (3 months) were used. For the analysis of the effects of SAK administration, the animals received intracerebroventricular (i.c.v.) administration of SAK at 1, 10 or 20 mg/kg (SAK1, SAK10 or SAK20, respectively) doses and the behavior was evaluated in the open field test (CA, 20 min), and immediately after the animals were submitted to the elevated plus-maze test (LCE, 5 min). Anticonvulsant effect was evaluated, thus SAK (1 or 10 mg / kg, i.c.v.) was previously administered in mice and after 30 min was injected with bicuculline (BIC, 1 mg/kg). Our main results showed that animals treated with SAK1 and SAK10 traveled a greater distance and higher speed (p < 0.05). In addition, SAK10-treated animals increased the entries frequency in enclosed arms compared with control animals (p < 0.05). SAK10-treated animals increased latency for first seizure (p < 0.05), survival percentage (p < 0.05) and percentage of time between time to first seizure and death (p < 0.05). Taken together, these results suggest that acute treatment with low dose SAK promotes hyperlocomotion (1 mg/kg), and high dose (20 mg/kg) induces anxiogenic effect in animals. Furthermore, intermediate dose (10 mg/kg) induces anxiety-like and hyperlocomotor behavior in animals, but there is anticonvulsant effect. Our next steps involve performing immunohistochemistry analysis to understand what brain areas are active during these behaviors and after investigate action mechanism involved in anticonvulsant effect.